Published in Am J Med on July 20, 1982
Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflammation (2010) 0.85
Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Pediatr Infect Dis J (2014) 0.85
Silicone-acyclovir controlled release devices suppress primary herpes simplex virus-2 and varicella zoster virus infections in vitro. Adv Pharmacol Sci (2013) 0.75
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med (1981) 3.19
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Controlled comparison of amikacin and gentamicin. N Engl J Med (1977) 2.62
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med (1984) 2.54
Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med (1980) 2.51
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis (1984) 2.44
Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet (1982) 2.28
Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis (1994) 2.13
Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination. J Virol (1990) 2.10
Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet (1978) 2.10
Chloramphenicol: an enzymological microassay. Antimicrob Agents Chemother (1976) 2.10
Letter: Febrile reactions after methicillin. Lancet (1974) 2.09
Probenecid and zidovudine metabolism. Lancet (1989) 1.99
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother (1998) 1.94
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS (1998) 1.58
Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med (1984) 1.57
Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis (1984) 1.52
Zidovudine with probenecid: a warning. Lancet (1990) 1.51
Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother (1979) 1.33
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1995) 1.32
Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res (1996) 1.29
Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother (1992) 1.29
Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther (1981) 1.27
Concentrations of gentamicin and amikacin in human kidneys. Antimicrob Agents Chemother (1976) 1.22
Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med (1983) 1.18
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med (1996) 1.18
Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med (1982) 1.16
Acute iron poisoning. A review. Am J Dis Child (1980) 1.14
Aminoglycoside inhibition of a renal phosphatidylinositol phospholipase C. J Pharmacol Exp Ther (1982) 1.14
Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med (1989) 1.13
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis (1997) 1.12
Nephrotoxicity induced by gentamicin and amikacin. Johns Hopkins Med J (1978) 1.10
A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr (1981) 1.09
Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. Antimicrob Agents Chemother (1982) 1.07
Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother (1982) 1.07
Oral chloramphenicol therapy. J Pediatr (1981) 1.03
Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial. Ann Intern Med (1984) 1.02
Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia. Antimicrob Agents Chemother (1978) 0.99
Netilmicin and gentamicin multidose kinetics in normal subjects. Clin Pharmacol Ther (1983) 0.99
Letter: Overdoses of chloramphenicol. JAMA (1975) 0.98
Chloramphenicol and the neonate--1979 view. Clin Perinatol (1979) 0.98
Mitochondrial protein synthesis: inhibition by emetine hydrochloride. Mol Pharmacol (1971) 0.97
The pharmacokinetics of amikacin in children. J Pediatr (1977) 0.96
Safety and tolerability of fluoroquinolones. Drugs (1993) 0.96
Adult cystinosis--a benign disorder. Am J Med (1966) 0.93
Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis (1986) 0.93
Evidence for luminal uptake of gentamicin in the perfused rat kidney. J Pharmacol Exp Ther (1979) 0.92
Mass spectral analysis of glucuronides. J Med Chem (1973) 0.92
Autoradiographic localization of [3H]gentamicin in the proximal renal tubules of mice. Antimicrob Agents Chemother (1979) 0.92
Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrob Agents Chemother (1994) 0.91
Emergency treatment of asthma. A comparison of two treatment regimens. JAMA (1979) 0.91
Cystinosis. Plasma cystine and cysteine concentrations and the effect of D-penicillamine and dietary treatment. Am J Med (1968) 0.90
Alterations of pigment epithelium in cystinosis. Arch Ophthalmol (1967) 0.90
Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine. Antimicrob Agents Chemother (1992) 0.90
Pharmacology of dantrolene sodium in children. Arch Phys Med Rehabil (1974) 0.89
Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. Antimicrob Agents Chemother (1987) 0.89
Gentamicin uptake by renal tubule brush border membrane vesicles. J Pharmacol Exp Ther (1980) 0.89
Neomycin inhibition of adenosine triphosphatase: evidence for a neomycin-phospholipid interaction. Antimicrob Agents Chemother (1980) 0.88
Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers. Antimicrob Agents Chemother (1993) 0.88
Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother (1991) 0.87
Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil (1974) 0.86
Inhibition of cytomegalovirus by rifampin. J Infect Dis (1972) 0.85
Effect of folate and folinate on 3H-thymidine incorporation by transforming human lymphocytes in vitro. Experientia (1977) 0.84
Acyclovir kinetics in end-stage renal disease. Clin Pharmacol Ther (1982) 0.83
Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1994) 0.82
Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Am J Med (1980) 0.81
Exchange transfusion in acute chloramphenicol toxicity. J Pediatr (1981) 0.81
Methicillin-associated fever. A double-blind comparison of methicillin from two manufacturers. Johns Hopkins Med J (1974) 0.81
A basic approach to the understanding of seizures and the mechanism of action and metabolism of anticonvulsants. Adv Pediatr (1973) 0.81
Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production. Hum Exp Toxicol (2004) 0.80
Metabolic fate of radioactive acyclovir in humans. Am J Med (1982) 0.80
Comparative cost effectiveness of gentamicin and tobramycin. Ann Intern Med (1984) 0.80
Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother (1983) 0.80
Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men. J Interferon Res (1987) 0.80
Iron and deferoxamine in lymphocyte blastogenesis. J Immunopharmacol (1980) 0.79
2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir. Antimicrob Agents Chemother (1993) 0.79
Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 0.79
Familial hyperglycinuria. New defect in renal tubular transport of glycine and imino acids. Am J Med (1973) 0.79
Commentary: a reappraisal of digitalis for infants with left-to-right shunts and "heart failure". J Pediatr (1978) 0.79
Prophylaxis: a strategy to minimise antiviral resistance. Lancet (1984) 0.79
The effect of co-trimoxazole on thymidine uptake by transforming human lymphocytes in vitro. J Pharm Pharmacol (1976) 0.78
Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med (1982) 0.78
Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother (1991) (1992) 0.78
Ceftriaxone compared with cefotaxime for serious bacterial infections. J Infect Dis (1989) 0.78
Effect of 'high-dose' amikacin in children. Dev Pharmacol Ther (1984) 0.77
Clinical evaluation of amoscanate in healthy male volunteers. Am J Trop Med Hyg (1986) 0.77
Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med (1986) 0.77
Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells. Antimicrob Agents Chemother (1996) 0.77
Phenytoin intoxication during concurrent diazepam therapy. J Neurol Neurosurg Psychiatry (1977) 0.77
Treatment and prevention of virus infections in immunosuppressed patients. Antiviral Res (1985) 0.77
Letter: Iron poisoning: another energy crisis. Lancet (1974) 0.76
Modulation of alpha-interferon's antiviral and clinical effects by aspirin, acetaminophen, and prednisone in healthy volunteers. Antiviral Res (1995) 0.76
Predicting aminoglycoside nephrotoxicity. JAMA (1986) 0.76
Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med (1982) 0.76
Effects of oral neomycin and kanamycin in chronic uremic patients: I. Urea metabolism. Kidney Int (1977) 0.76
Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in humans. Clin Pharmacol Ther (1988) 0.76
Rapid acyclovir radioimmunoassay, using charcoal adsorption. Antimicrob Agents Chemother (1982) 0.75
Lack of beta-oxidation defects in human immunodeficiency virus-positive subjects with and without chronic zidovudine exposure. Blood (1996) 0.75
Enzymatic acylation of phenylalanyl transfer ibonucleic acids from mitochondri and cytosol of rat liver. J Biol Chem (1968) 0.75